Unknown

Dataset Information

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.


ABSTRACT:

Aim

Post-hoc analysis of the efficacy and safety of ertugliflozin in East/Southeast (E/SE) Asian patients with type 2 diabetes mellitus (T2DM).

Materials and methods

Efficacy evaluations used data from randomized, double-blind, phase 3 studies: a pool of two 26-week placebo-controlled studies and one 52-week active-comparator (glimepiride) study. Least squares mean change from baseline was calculated for HbA1c, fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events based on pooled data (broad pool) from seven phase 3 studies (including studies in the efficacy analysis).

Results

Among 161 E/SE Asian patients in the placebo pool (ertugliflozin, n = 106), ertugliflozin reduced H

SUBMITTER: Liu J 

PROVIDER: S-EPMC7078752 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature